Company: LIMN
Filing Date: 2025-08-13
Form Type: 424B3
Source: 0001410578-25-001746
Chunk: 61

Company: Liminatus Pharma, Inc.
Filing Date: 2025-08-13
Form: 424B3
Chunk 61
---
 provisions or its anti-bribery provisions, or provisions of anti-corruption or anti-bribery laws in other countries. |

Any of these factors could significantly harm our future international expansion and operations and, consequently, our results of operations. Risks Related to Liminatus’s Intellectual Property The Business Combination may give counterparties to the license agreements to which we are party (or by which we are otherwise affected) the ability to exercise rights and remedies under such agreements which, if exercised, may have material adverse consequences. There is ambiguity as to whether the transactions contemplated by the Business Combination, including the Liminatus Merger, may be considered a change of control under certain intellectual property and technology licenses that are important to our business, including the CD47 License with InnoBation, entitling the counterparty or beneficiary to exercise certain rights and remedies. If the Business Combination is deemed to be a change of control for purposes of these agreements, the counterparty or beneficiary could have the ability, depending on the arrangement, to, among other things, make Liminatus’ exclusive license to become a non-exclusive license, declare a breach of, or default under, any assignment provision or change of control provision of the agreements, or terminate the agreements, unless they otherwise provide consent to the deemed change of control. We have not obtained the consent of the counterparties or beneficiaries of such agreements with respect to the Business Combination. We intend to enter into discussions with the counterparties where appropriate to seek a waiver under, or amendment of, the agreements to avoid or minimize any potential adverse consequences. We cannot assure you that we will be successful in avoiding or minimizing the adverse consequences which, individually or collectively, may have a material adverse effect on our ability to successfully develop and, if approved, commercialize our current and any future product candidates or implement our plans and strategies (which do not reflect the impact of any such adverse consequences, financial or otherwise), and we could be adversely affected. Liminatus’s proprietary rights may not adequately protect our intellectual property and potential products, and if Liminatus cannot obtain adequate protection of its intellectual property and potential products, it may not be able to successfully market its potential products. Liminatus’s commercial success will depend in part on obtaining and maintaining intellectual property protection for our products, formulations, processes, methods and other technologies. Liminatus will only be able to protect these technologies and products from unauthorized use by third parties to the extent that valid and enforceable intellectual property rights, including patents, cover them, or other